BioCentury
ARTICLE | Politics & Policy

ASCO outlines position on cancer drug pricing

July 19, 2017 9:39 PM UTC

In a statement released Wednesday, the American Society of Clinical Oncology outlined its position on ways to address cancer drugs' affordability.

ASCO said it supports testing various strategies, including value-based pathways, indication-based pricing and outcomes-based pricing. Anthem Inc. (NYSE:ANTM) has been using value-based pathway models in oncology, and Express Scripts Holding Co. (NASDAQ:ESRX) is using an indication-based pricing model (see BioCentury, June 2, 2014 & March 28, 2016)...